The Pharmacy Times® Oncology resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.
What can we help you find?
The FDA has approved Erleada (apalutamide) for the treatment of metastatic castration-sensitive prostate cancer (mCSPC), based on the results from the Phase 3 TITAN study.
Patients with metastatic colorectal cancer harboring certain non-V600 BRAF mutations may benefit from anti-EGFR treatment.
Hematology and oncology pharmacists discussed patient outreach at a panel during the Hematology/Oncology Pharmacy Association’s (HOPA) annual conference in April.
Despite advances in cancer care, patients typically face obstacles to treatment.
During a presentation at the recent Community Oncology Alliance Annual Conference in Orlando, Florida, Ray Bailey, RPh, discussed the implications of medical marijuana for patients with cancer.
As the cost of treating the disease has risen, so too have the direct medical care expenses that patients pay out of pocket, as commercial insurers increasingly shift the burden of paying for treatment to patients through higher premiums, deductibles, and co-pays.
The FDA approval of pembrolizumab plus lenvatinib for this new indication is the first under a new international collaboration with Australia and Canada.
Study finds association between obesity and a greater burden of symptoms and distress among patients with breast or prostate cancer.
Puma’s supplemental New Drug Application is seeking approval for the use neratinib (Nerlynx) plus capecitabine as a third-line treatment in patients with human epidermal growth receptor 2-positive metastatic breast cancer.
As a nonprofit focused on enhancing patient care. COPA is in a unique position to serve as a noncommercial organization dedicated to addressing community oncology pharmacy issues, all in the sole interest of patient care.
Immunotherapy methods emerged on the oncology market as adoptive cell transfers, specifically chimeric antigen receptor (CAR) T-cell therapies, with clear benefits in hematologic malignancy treatment.
Investigational Drug for Treating Aggressive Form of NSCLC Granted FDA's Breakthrough Therapy Designation
There are currently no FDA-approved targeted therapies to treat metastatic MET exon14 skipping-mutated non-small cell lung cancer (NSCLC), according to the Novartis.
+ Load More